Accuracy and Precision of the SynchroMed II Pump

Farid, Reza; Binz, Kirstin; Emerson, Jane A.; Murdock, Fred

doi:10.1111/ner.12934

Cited by 11 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two key technical and procedural areas for improvement exist with regards to CNS infusion. First, harnessing technology such as the Synchromed II intrathecal baclofen pump (Medtronic, Minneapolis MN USA) could allow for a slower, more continuous infusion of intrathecal agent without the need of repeated percutaneous access [22] . However, currently there are several barriers including the stability of a stored cellular product within an intrathecal continuous delivery system.…”

Section: Discussionmentioning

confidence: 99%

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

et al. 2023

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

et al. 2023

View full text Add to dashboard Cite

“…The actuation of the IMRD was based solely on magnetic force without any other power sources, thereby eliminating batteries or electronics. This would allow for smaller dimensions and long‐term operation of the device after implantation compared to other implantable devices for on‐demand drug delivery 48,49 . The device size can be further reduced when fabricated in a more sophisticated manufacturing facility 50 .…”

Section: Discussionmentioning

confidence: 99%

“…Considering translational applications, the actuation device housing may need to be made of harder materials, such as metals, to better protect the drug in the device after implantation 48,52 . In our prototype, 12 separate drug reservoirs were used.…”

Section: Discussionmentioning

confidence: 99%

Implantable device with magnetically rotating disk for needle‐free administrations of emergency drug

Kim

Han

Kim

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Prompt administration of first‐aid drugs can save lives during medical emergencies such as anaphylaxis and hypoglycemia. However, this is often performed by needle self‐injection, which is not easy for patients under emergency conditions. Therefore, we propose an implantable device capable of on‐demand administration of first‐aid drugs (i.e., the implantable device with a magnetically rotating disk [iMRD]), such as epinephrine and glucagon, via a noninvasive simple application of the magnet from the outside skin (i.e., the external magnet). The iMRD contained a disk embedded with a magnet, as well as multiple drug reservoirs that were sealed with a membrane, which was designed to rotate at a precise angle only when the external magnet was applied. During this rotation, the membrane on a designated single‐drug reservoir was aligned and torn to expose the drug to the outside. When implanted in living animals, the iMRD, actuated by an external magnet, delivers epinephrine and glucagon, similar to conventional subcutaneous needle injections.

show abstract

“…Its original iteration, SynchroMed , was approved by FDA in 1991. The list of Synchromed II therapeutic payloads includes baclofen (for the reduction in severe spasticity), morphine, and Ziconotide (for pain management) [ 59 , 60 ].…”

Section: Iddss and Fbr: Current Clinical Landscapementioning

confidence: 99%

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

et al. 2021

View full text Add to dashboard Cite

Precise delivery of therapeutics to the target structures is essential for treatment efficiency and safety. Drug administration via conventional routes requires overcoming multiple transport barriers to achieve and maintain the local drug concentration and commonly results in unwanted off-target effects. Patients’ compliance with the treatment schedule remains another challenge. Implantable drug delivery systems (IDDSs) provide a way to solve these problems. IDDSs are bioengineering devices surgically placed inside the patient’s tissues to avoid first-pass metabolism and reduce the systemic toxicity of the drug by eluting the therapeutic payload in the vicinity of the target tissues. IDDSs present an impressive example of successful translation of the research and engineering findings to the patient’s bedside. It is envisaged that the IDDS technologies will grow exponentially in the coming years. However, to pave the way for this progress, it is essential to learn lessons from the past and present of IDDSs clinical applications. The efficiency and safety of the drug-eluting implants depend on the interactions between the device and the hosting tissues. In this review, we address this need and analyze the clinical landscape of the FDA-approved IDDSs applications in the context of the foreign body reaction, a key aspect of implant–tissue integration.

show abstract

Accuracy and Precision of the SynchroMed II Pump

Cited by 11 publications

References 3 publications

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Implantable device with magnetically rotating disk for needle‐free administrations of emergency drug

Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape

Contact Info

Product

Resources

About